Project Grant W81XWH1710310

The National Cancer Institute (NCI) awarded a $456,414 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, for a research project titled "B7-H3 CAR T Cells Following Initial Radiation for Children and Young Adults with Diffuse Intrinsic Pontine Glioma." The project aims to define the efficacy of B7-H3 chimeric antigen receptor (CAR) T cell therapy for children with diffuse...

This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to improve immunogene therapy for the treatment of glioblastoma, a highly fatal type of brain cancer. The $633,656 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will support preclinical research to investigate...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $553,167 to The Washington University to conduct a multi-institutional Phase I/II clinical trial evaluating the safety, efficacy, and immunogenicity of a peptide vaccine (PEP-CMV) in combination with checkpoint blockade therapy for the treatment of pediatric brain cancers, including diffuse midline glioma, high-grade glioma, medulloblastoma, and ependymoma. The trial aims to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute, Inc. (DFCI) to improve survival for children with diffuse midline gliomas (DMG), a rare and deadly type of brain cancer. The $1,243,002 award aims to enhance the efficacy of radiotherapy for DMG by exploiting synthetic lethal vulnerabilities. Key objectives include: Testing the hypothesis that combining radiation with antagonists of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The $399,669 grant, awarded on September 3, 2024, will support the development of an autologous ATCT that targets multiple GBM-specific antigens unique to each patient. The key innovation is the use of Prussian...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this award include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop new metabolic therapy and imaging approaches for treating diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The key products and services to be delivered include: Determining if combined inhibition of the enzymes G6PD and...

The National Cancer Institute (NCI) awarded a $576,659 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Emory University in Atlanta, Georgia. The project, titled "Tumor and Host Immune Signatures Associated with Health Disparities in Outcomes Following GD2 Immunotherapy in Neuroblastoma," aims to investigate racial differences in immune cell profiles that may contribute to outcome disparities in high-risk neuroblastoma patients receiving GD2 antibody...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) in the amount of $686,979 will support research aimed at understanding and disrupting metabolic mechanisms of immunosuppression in diffuse midline gliomas (DMGs), an aggressive form of childhood brain cancer. The key objectives are to: 1) delineate how the H3K27M mutation in DMGs upregulates the glycolytic enzyme PGK1 to...

This $249,645 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The Children's Hospital Corporation (Boston Children's Hospital) aims to develop a novel immunotherapy strategy using gene-edited, tumor-specific B cells. The goal is to leverage the tumor-suppressing and immune-stimulating functions of these engineered B cells to enhance anti-cancer immunity. The project will exploit an optimized B cell gene editing protocol to redirect the...